US31573L1052
© Globe Newswire
15.12.2025
FBLG
LISTED
NASDAQ
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
News Preview
HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
FBLG
LISTED
NASDAQ
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
News Preview
Platform Poised to Expand into Joint and Cartilage Repair Platform Poised to Expand into Joint and Cartilage Repair...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
FBLG
LISTED
NASDAQ
FibroBiologics Announces Payoff of Outstanding Debt
News Preview
Repayment of convertible promissory notes strengthens balance sheet and eliminates further dilution from conversions Repayment of convertible promissory notes strengthens balance sheet and eliminates further dilution from conversions...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
20.11.2025
FBLG
LISTED
NASDAQ
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
News Preview
HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has rece...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
20.11.2025
FBLG
LISTED
NASDAQ
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
News Preview
HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2025
FBLG
LISTED
NASDAQ
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
News Preview
HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
FBLG
LISTED
NASDAQ
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients ...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
FBLG
LISTED
NASDAQ
FibroBiologics to Present at Bio-Europe 2025
News Preview
HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
FBLG
LISTED
NASDAQ
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
News Preview
HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scie...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2025
FBLG
LISTED
NASDAQ
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
News Preview
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the publication...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
FBLG
LISTED
NASDAQ
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
News Preview
Pilot studies underway to advance IND-enabling preclinical development Pilot studies underway to advance IND-enabling preclinical development...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
FBLG
LISTED
NASDAQ
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
News Preview
Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical translation of the Bone Marrow Organoid technology Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical t...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
27.08.2025
FBLG
LISTED
NASDAQ
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chief...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
FBLG
LISTED
NASDAQ
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News Preview
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2025
FBLG
LISTED
NASDAQ
FibroBiologics to Present at the Advanced Wound Care Summit USA
News Preview
HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.07.2025
FBLG
LISTED
NASDAQ
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
News Preview
HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors t...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.06.2025
FBLG
LISTED
NASDAQ
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
News Preview
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has closed th...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.06.2025
FBLG
LISTED
NASDAQ
FibroBiologics to Present at the BIO International Convention 2025
News Preview
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
FBLG
LISTED
NASDAQ
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025 Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diab...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.04.2025
FBLG
LISTED
NASDAQ
FibroBiologics Presents at the ThymUS 2025 Meeting
News Preview
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebr...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
FBLG
LISTED
NASDAQ
FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux
News Preview
HOUSTON, 03 avr. 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq : FBLG), ou « FibroBiologics », une société de biotechnologie au stade clinique détenant plus de 240 brevets délivrés et en instance portant sur le développement de thérapies et de traitements potentiels pour les maladies chroniques à base de fibroblastes et des matériaux déri...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
FBLG
LISTED
NASDAQ
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
News Preview
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
FBLG
LISTED
NASDAQ
FibroBiologics dépose une demande de brevet pour une nouvelle approche visant à moduler l’activité mitochondriale à l’aide de produits thérapeutiques à base de fibroblastes
News Preview
Cette nouvelle méthode pourrait ouvrir la voie vers de nouvelles options thérapeutiques ciblées sur des maladies chroniques causées par un dysfonctionnement mitochondrial....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.02.2025
FBLG
LISTED
NASDAQ
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
News Preview
FibroBiologics to also present at the BIO CEO & Investor Conference FibroBiologics to also present at the BIO CEO & Investor Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.12.2024
FBLG
LISTED
NASDAQ
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
News Preview
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has closed the...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2024
FBLG
LISTED
NASDAQ
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
News Preview
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application cover...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
FBLG
LISTED
NASDAQ
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
News Preview
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
FBLG
LISTED
NASDAQ
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
FBLG
LISTED
NASDAQ
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
News Preview
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced promising new finding...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2024
FBLG
LISTED
NASDAQ
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
News Preview
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
FBLG
LISTED
NASDAQ
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
News Preview
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of a paten...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.10.2024
FBLG
LISTED
NASDAQ
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
News Preview
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O’Heer...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2024
FBLG
LISTED
NASDAQ
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
News Preview
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2024
FBLG
LISTED
NASDAQ
FibroBiologics Engages Southern Star Research as CRO in Australia
News Preview
Southern Star Research will provide CRO services for FibroBiologics in Australia Southern Star Research will provide CRO services for FibroBiologics in Australia...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2024
FBLG
LISTED
NASDAQ
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
News Preview
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a paten...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2024
FBLG
LISTED
NASDAQ
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chie...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2024
FBLG
LISTED
NASDAQ
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
News Preview
HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2024
FBLG
LISTED
NASDAQ
FibroBiologics Files 2024 Second Quarter Report
News Preview
HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.07.2024
FBLG
LISTED
NASDAQ
FibroBiologics to Present at JonesTrading Healthcare Summit 2024
News Preview
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
FBLG
LISTED
NASDAQ
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
News Preview
HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the development of a...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.06.2024
FBLG
LISTED
NASDAQ
FibroBiologics Set to Join Russell 2000® Index
News Preview
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to jo...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2024
FBLG
LISTED
NASDAQ
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
News Preview
HOUSTON, June 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Chief Scientific...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2024
FBLG
LISTED
NASDAQ
FibroBiologics Files 2024 First Quarter Report
News Preview
HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q f...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
FBLG
LISTED
NASDAQ
FibroBiologics to Present at the BIO International Convention 2024
News Preview
HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
